Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Jan. 6, 2025 — Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer ... Scientists Develop Scans That Light-Up Aggressive ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

Michael Truskoski learned he has stage 4 lung cancer after he had a seizure at work just over three weeks ago, the result of cancer that spread to his brain.

Researchers from the University of Michigan have developed a way of detecting circulating tumor cells in the bloodstream of ...

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...

The lungs are a tempting place for cancer cells -- so much so that more than half of people with advanced cancer elsewh ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to ...

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis being the primary contributor to poor patient outcomes.

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.